<DOC>
	<DOC>NCT01409018</DOC>
	<brief_summary>This study investigated repeated-dose pharmacokinetics and safety of itraconazole and its active metabolite hydroxyitraconazole in pediatric cancer patients at risk for the development of invasive fungal disease.</brief_summary>
	<brief_title>Pharmacokinetics of Itraconazole in Pediatric Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Pediatric patients who are under chemotherapy, and receive itraconazole. 1. Patients with significant functional deficits in major organs, but the following eligibility criteria may be modified in individual cases. Heart : fractional shortening &lt; 30%, ejection fraction &lt; 45% Liver : total bilirubin ≥ 2 x upper limit of normal (ULN) ; aminotransferase ≥ 3 x ULN Kidney : creatinine ≥ 2 x normal or GFR ≤ 60㎖/min/1.73㎡ 2. Patients with hypersensitivity to azoles. 3. Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study. 4. Pregnant or nursing women. 5. Psychiatric disorder that would preclude compliance.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>pediatric</keyword>
	<keyword>cancer</keyword>
	<keyword>invasive fungal disease</keyword>
	<keyword>antifungal agent</keyword>
</DOC>